Investing.comQwen · 实盘不做把握 3/10不做原因:已被定价
北京时间·🕒 发布 03:32:41·⟳ 抓取 03:33:50 +1m09s·⚡ 决策 08-28 03:40:43 +6m53s·60.5 天前
FDA批准Roivant子公司Priovant的Lisraya(brepocitinib)治疗皮肌炎，为first-in-class TYK2/JAK1抑制剂
FDA批准是已公开流程（优先审评→孤儿药→三期阳性→NDA受理）的程序性落地，非新增预期差。股价13周涨26%至52周高位附近，今日仅+1.65%确认市场已提前定价。大市值（约$25B+）下单个罕见病适应证的收入增量对估值边际影响有限。搜索基础设施故障导致无法核实先例和分析师峰值销售预期，进一步降低置信度。
📄 原文Investing.com↗ 原文
FDA approves Priovant’s Lisraya for dermatomyositis treatment
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook DURHAM, N.C. - Priovant Therapeutics ann…
不做 Roivant Sciences（ROIV.US）
FDA批准是已公开流程的程序性落地（优先审评+孤儿药+三期阳性→批准），非新增预期差。股价13周涨26%至52周高位附近（-3.2%），今日仅+1.65%确认无增量surprise。大市值下单个罕见病适应证边际弹性不足。无剩余edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FDA批准brepocitinib治疗皮肌炎是方向明确的正面事件，但该批准是已知流程（优先审评+孤儿药资格+VALOR三期阳性数据均已公开）的预期结果。ROIV股价13周从基准涨26%至$37.35（距52周高仅-3.2%），20日累计+11.8%，今日批准公布后仅涨1.65%，表明市场已充分定价。皮肌炎为罕见病（美国患病率约0.1-6/10万），孤儿药定价虽高但患者池有限，对约$25B市值的Roivant边际弹性不足。结论：方向正确但无剩余edge，不做。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 medium · price-in 风险 high ↗
消息传播链
- Investing.com AI生成文章报道FDA批准，引用公司新闻稿内容；未找到公司IR或FDA官网原始链接（搜索基础设施故障）市场反应:ROIV盘中+1.65%至$37.355，反应温和
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
搜索完全失败，无法获取反证；但基于股价已在高位且今日反应温和，price-in本身即为最强反证
检索:Roivant brepocitinib peak sales analyst estimate market cap
先例如何影响了这次决策
对本次决策的影响:先例缺失使得无法用历史数据校准涨幅量级和胜率；但基于price-in分析（股价近高位+今日反应温和）已足以支持AVOID结论
方向:无法确定——搜索基础设施完全故障（Tavily配额耗尽，Bing后备返回无关结果），无法检索到任何真实历史先例
涨幅量级:无法校准——未获得任何可用先例
形态:无法判断见光死模式
工具执行结果 · 成功 10 · 降级 0 · 失败 1 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 649 ms
{ - search_processed_events 成功 stock_tools HTTP · 1,677 ms
{"result": "search_processed_events:agent query=`priovant lisraya brepocitinib fda approval dermatomyositis | roivant brepocitinib fda approved | tyk2 jak1 inhibitor dermatomyositis fda`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.5/72 小时、11877 条本臂决策(完整)，返回 1 条候选。\n• 08-26 15:15 UTC(CST 23:15) [ticker] 不做 ROIV.US ( - stock_quote 成功 stock_tools HTTP · 560 ms
{ - web_search 成功 Bing RSS(Tavily 降级后备) · 873 ms
web_search「Roivant Priovant brepocitinib Lisraya FDA approved dermatomyositis 2026」命中 8 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})： - web_search 成功 Bing RSS(Tavily 降级后备) · 1,022 ms
web_search「dermatomyositis market size brepocitinib peak sales forecast analyst」命中 8 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})： - search_case_library 成功 stock_tools HTTP · 359 ms
{"result": "search_case_library「ROIV.US」无历史决策命中(我们过去没在这些标的上决策过,或历史尚未回填)。\n◆ ROIV.US：相关历史决策 9 条 · 其中该标的 ENTER 1 条(11.1%) · 已结算 1 笔 · 胜率 0% · 中位 -0.46% · 均值 -0.46% ⚠️只有 1 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那只票自己的腿。"} - kb_search 失败 stock_tools HTTP · 18,734 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 Bing RSS(Tavily 降级后备) · 1,243 ms
web_search「"brepocitinib" "FDA" approval dermatomyositis Priovant Roivant August 2026」命中 8 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})： - web_search 成功 Bing RSS(Tavily 降级后备) · 933 ms
web_search「Roivant Sciences market cap revenue pipeline 2026」命中 8 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})： - web_search 成功 Bing RSS(Tavily 降级后备) · 1,175 ms
web_search「brepocitinib pipeline indications Roivant Priovant clinical trials」命中 8 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})： - web_search 成功 Bing RSS(Tavily 降级后备) · 1,122 ms
web_search「FDA approval biotech stock reaction orphan drug small cap 2025 2026」命中 8 条(Bing RSS 后备；Tavily: HTTP 432 {"detail":{"error":"This request exceeds your plan's set usage limit. Please upgrade your plan or contact support@tavily.com"}})：
原文全文
展开原文 · 2,044 字
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook
DURHAM, N.C. - Priovant Therapeutics announced today that the U.S. Food and Drug Administration has approved Lisraya (brepocitinib) 30 mg for the treatment of adults with dermatomyositis, according to a company press release.
Dermatomyositis is a rare systemic autoimmune disease characterized by progressive muscle weakness and skin lesions. Lisraya is a once-daily oral pill described as a first-in-class TYK2/JAK1 inhibitor and is available immediately in the United States.
The approval follows the Phase 3 VALOR trial, which the company states was the largest dermatomyositis clinical trial conducted. In the 52-week study, 55% of patients treated with Lisraya achieved moderate or better improvement on the myositis Total Improvement Score and minimal or no steroid use, compared to 30% on placebo.
Among patients taking at least 7.5 mg per day of oral corticosteroids at baseline, 62% of those receiving Lisraya tapered to minimal or no steroid use by the end of the study, compared with 38% on placebo. Additionally, 45% discontinued corticosteroids entirely, compared with 29% on placebo.
The most common adverse reactions in the VALOR trial were upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, fall, influenza, and acne.
The drug carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The FDA previously granted Lisraya Priority Review and Orphan Drug Designation.
Priovant stated that eligible patients may pay as little as $0 per month through the Lisraya My Compass Support program. The drug is available through a limited distribution network of specialty pharmacies.
Priovant Therapeutics is a biotechnology company focused on autoimmune diseases and is a Roivant (NASDAQ:ROIV) company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
DURHAM, N.C. - Priovant Therapeutics announced today that the U.S. Food and Drug Administration has approved Lisraya (brepocitinib) 30 mg for the treatment of adults with dermatomyositis, according to a company press release.
Dermatomyositis is a rare systemic autoimmune disease characterized by progressive muscle weakness and skin lesions. Lisraya is a once-daily oral pill described as a first-in-class TYK2/JAK1 inhibitor and is available immediately in the United States.
The approval follows the Phase 3 VALOR trial, which the company states was the largest dermatomyositis clinical trial conducted. In the 52-week study, 55% of patients treated with Lisraya achieved moderate or better improvement on the myositis Total Improvement Score and minimal or no steroid use, compared to 30% on placebo.
Among patients taking at least 7.5 mg per day of oral corticosteroids at baseline, 62% of those receiving Lisraya tapered to minimal or no steroid use by the end of the study, compared with 38% on placebo. Additionally, 45% discontinued corticosteroids entirely, compared with 29% on placebo.
The most common adverse reactions in the VALOR trial were upper respiratory tract infection, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, fall, influenza, and acne.
The drug carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The FDA previously granted Lisraya Priority Review and Orphan Drug Designation.
Priovant stated that eligible patients may pay as little as $0 per month through the Lisraya My Compass Support program. The drug is available through a limited distribution network of specialty pharmacies.
Priovant Therapeutics is a biotechnology company focused on autoimmune diseases and is a Roivant (NASDAQ:ROIV) company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。